Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 8, 2010

View Archived Issues

Prucalopride is safe and efficacious in opioid-induced constipation

Amantadine and fluoxetine display comparable efficacy in major depressive disorder

Technetium-99m-labeled MIP-1340 shows suitability for prostate cancer imaging

Banyu Pharmaceutical discloses new DGAT-1 inhibitors

OriBase Pharma describes new tyrosine protein kinase inhibitors

Italian scientists synthesize new HDAC inhibitor

Ivabradine improves outcome of patients with heart failure in SHIFT trial

BioFocus and Usher III Initiative partner to discover drugs for Usher's syndrome type III

AstraZeneca identifies new histamine H3 receptor antagonists

CytRx begins phase II bafetinib trial in advanced prostate cancer

Shionogi claims new P2X3 and P2X2/3 receptor antagonists

Rexahn submits protocol to FDA for phase IIb RX-10100 trial

Arrow Therapeutics discloses new antivirals for HCV infection

La Jolla Pharma seeks candidate small-molecule therapeutics to inlicense or acquire

Promedior begins phase IIa trial of PRM-151 for postsurgical scarring in glaucoma

Somaxon launches Silenor in U.S. for insomnia

FDA clears IND for Tekmira's TKM-PLK1

Enrollment reinitiated in phase III trial of zanolimumab in CTCL

Merz Pharma Canada's Xeomin to be listed with regular benefit status

Idenix's IDX-184 and IDX-320 programs in HCV infection on clinical hold

Phase III REALIZE trial of telaprevir in HCV infection meets primary endpoint

Onyx and Ono sign Japanese agreements for oncology drugs carfilzomib and ONX-0912

Thomson Reuters salutes winner of 2010 IUPAC-Richter Prize in Medicinal Chemistry

Can-Fite files IND application for phase III CF-101 trial in dry eye syndrome

Abbott acquires Piramal's Healthcare Solutions business

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 9, 2025.
Corestemchemon preps US BLA filing for stem cell ALS therapy
BioWorld
Corestemchemon Inc. is planning to file a BLA for Neuronata-R (lenzumestrocel) by the end of 2025 to gain accelerated approval from the U.S. FDA, company...
In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol
BioWorld
In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
Omada, Caris arrivals continue med-tech IPO hot streak
BioWorld MedTech
Omada Health Inc. rang the opening bell on the New York Stock Exchange on June 6, marking its first day as a public company, but it won’t be the most recent IPO...